Two UTSW Scientists Awarded Ross Prize for Groundbreaking Research in Dyslipidemias & Metabolic Liver Disease

(left to right) Helen H. Hobbs, MD, and Jonathan C. Cohen, PhD

The Feinstein Institutes for Medical Research has selected two scientists from UT Southwestern Medical Center, Helen H. Hobbs, MD, and Jonathan C. Cohen, PhD, to receive the 10th annual Ross Prize in Molecular Medicine for groundbreaking research in dyslipidemias and metabolic liver disease. The duo was the first to discover the genetic cause of fatty liver disease in humans, and their ongoing work has led to a new class of cholesterol-lowering drugs.

Established in 2013, the Ross Prize is awarded annually through the Feinstein Institutes’ peer-reviewed, open-access journal Molecular Medicine. The prize includes a $50,000 award for each recipient and is given to investigators whose research shows high potential for transforming how we treat and cure disease.